scispace - formally typeset
Open AccessJournal ArticleDOI

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

TLDR
In the PCOS group, metformin therapy improved hirsutism and menstrual cycles significantly more than placebo, and in both PCOS and control women, however, met formin treatment reduced body weight and BMI significantlyMore than placebo.
Abstract
Abdominal obesity and hyperinsulinemia play a key role in the development of the polycystic ovary syndrome (PCOS). Dietary-induced weight loss and the administration of insulin-lowering drugs, such as metformin, are usually followed by improved hyperandrogenism and related clinical abnormalities. This study was carried out to evaluate the effects of combined hypocaloric diet and metformin on body weight, fat distribution, the glucose-insulin system, and hormones in a group of 20 obese PCOS women[ body mass index (BMI) > 28 kg/m2] with the abdominal phenotype (waist to hip ratio >0.80), and an appropriate control group of 20 obese women who were comparable for age and pattern of body fat distribution but without PCOS. At baseline, we measured sex hormone, sex hormone-binding globulin (SHBG), and leptin blood concentrations and performed an oral glucose tolerance test and computerized tomography (CT) at the L4-L5 level, to measure sc adipose tissue area (SAT) and visceral adipose tissue area. All women were...

read more

Citations
More filters
Journal ArticleDOI

Metformin: an update.

TL;DR: Treatment with an insulin-sensitizing agent, such as metformin, in patients with type 2 diabetes mellitus may correct several of the primary pathophysiological abnormalities of the metabolic syndrome.
Book

Polycystic Ovary Syndrome

TL;DR: It is of interest to realize that polycystic ovary syndrome has moved from a histology diagnosis of ovarian tissue to a heterogeneous clinical syndrome, to a reproductive endocrine abnormality with elevated serum luteinizing hormone and androgen levels, and to a metabolic disease characterized by hyperinsulinemia and dyslipidemia.
Journal ArticleDOI

Obesity and the polycystic ovary syndrome

TL;DR: Irrespective of the pathogenetic mechanism involved, obese PCOS women have more severe hyperandrogenism and related clinical features (such as hirsutism, menstrual abnormalities and anovulation) than normal-weight PCos women.
Journal ArticleDOI

Metformin in polycystic ovary syndrome: systematic review and meta-analysis

TL;DR: Metformin is an effective treatment for anovulation in women with polycystic ovary syndrome and its choice as a first line agent seems justified, and there is some evidence of benefit on variables of the metabolic syndrome.
References
More filters
Journal ArticleDOI

Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans

TL;DR: Serum leptin concentrations are correlated with the percentage of body fat, suggesting that most obese persons are insensitive to endogenous leptin production.
Journal ArticleDOI

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

TL;DR: Since PCOS usually has a menarchal age of onset, this makes it a particularly appropriate disorder in which to examine the ontogeny of defects in carbohydrate metabolism and for ascertaining large three-generation kindreds for positional cloning studies to identify NIDDM genes.
Journal ArticleDOI

Polycystic ovary syndrome.

TL;DR: It is now clear that the range of presenting symptoms of women with polycystic ovaries includes not only nonhirsute women with oligomenorrhoea or amenorrhOEa but also hirsute subjects with regular, ovulatory cycles.
Book

Polycystic Ovary Syndrome

TL;DR: It is of interest to realize that polycystic ovary syndrome has moved from a histology diagnosis of ovarian tissue to a heterogeneous clinical syndrome, to a reproductive endocrine abnormality with elevated serum luteinizing hormone and androgen levels, and to a metabolic disease characterized by hyperinsulinemia and dyslipidemia.
Journal ArticleDOI

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy☆

TL;DR: Using polycystic ovary syndrome as a model of insulin resistance and hyperandrogenism, the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS was assessed.
Related Papers (5)